Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: J Hematop. 2018 Aug 9;11(3):67–74. doi: 10.1007/s12308-018-0329-z

Table 1.

Patient characteristics

Age
(years)/sex		 WBC at
diagnosis
(/mcL)		 Platelets at
diagnosis
(/mcL)		 Immunophenotype Karyotype Oncoprotein Myeloid mutations Outcome
Patient 1 29/F 23,000 32,000 CD34, CD117, HLA-DR, CD38, CD71, CD33, CD11b, CD11c, CD13, CD7, cMPO, cTDT, cCD3 46,XX,t(15;17)(q24q21)[20]. nuc ish(PML,RARA)x3,(PML con RARA)x2[183/200] PML/RARα
bcr3 isoform		 FLT3-ITD (p.Glu604_Phe605ins6. C.1794_1811dup) Ongoing CR
(22 months after diagnosis)
Patient 2 50/M 20,000 11,000 CD34 (partial), CD117, HLA-DR, CD38, CD71, CD64, CD33, CD13, CD11c, cMPO (dim), cCD3 46,XY,t(15;17)(q24;q21)[20]. nuc ish(PML,RARA)x3,(PML con RARA)x2[183/200],(RARAx2)(5′ RARA sep 3′RARAx1)[179/200] -- FLT3-ITD (p.Tyr599_Pro606dup. c.1795_1818dup), ASXL1 (p.Pro779Leu) Ongoing CR
(19 months after diagnosis)

ASXL1 = additional sex combs like 1; c = cytoplasmic; CR = complete remission; F = female; FLT3-ITD = FMS-like tyrosine kinase 3 receptor internal tandem duplication; M = male; PML/RARα = promyelocytic leukemia/retinoic acid receptor alpha; TDT = terminal deoxynucleotidyl transferase; WBC = white blood cells